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Introduction {#sec005}
============

Liver cancer is one of the most frequently diagnosed malignancies and the fourth leading cause of death from cancer worldwide. On the basis of annual projections, the World Health Organization estimates that more than one million patients will die from liver cancer in 2030 \[[@pone.0236622.ref001]\]. According to 2019 cancer statistics, the incidence of liver cancer is rising faster than that of any other cancer in both men and women in the United States \[[@pone.0236622.ref002]\]. Chronic hepatitis C virus (HCV) or chronic hepatitis B virus (HBV) infections, alcohol abuse, and nonalcoholic steatohepatitis are the main risk factors for this disease \[[@pone.0236622.ref003]\]. Despite the rapid progress being made in surgical techniques, which are the primary therapies for liver cancer, in combination with adjuvant chemotherapy or radiotherapy, patients with liver cancer frequently relapse following liver resection \[[@pone.0236622.ref004]\]. However, 70% to 80% of patients cannot benefit from surgery because they are diagnosed at an advanced stage and are only eligible for palliative care. In recent years, preclinical researches and clinical trials have offered many opportunities for the development of liver cancer treatment. Immune therapeutic strategies have been proven safe and effective \[[@pone.0236622.ref005]\]. Unlike conventional cancer therapies, immunotherapeutic approaches do not directly target tumor cells; instead, they target the patient's immune system or the tumor microenvironment(TME) \[[@pone.0236622.ref006]\]. A variety of strategies have been explored: cytokine administration, cancer vaccines, adoptive cellular therapy and immune checkpoint blockade (ICB) \[[@pone.0236622.ref007]\]. Among which, ICB have been subject to cancer immunotherapy due to its promising outcomes across multiple advanced solid malignancies, including hepatocellular carcinoma (HCC). The key mechanism of action for ICB is to block the immune exhaustion or inhibitory pathways induced by chronic immune response against tumor antigen, in order to reactivate the antitumor immune response. PD-1, PD-L1, and CTLA-4 inhibitors are the most widely evaluated ICB therapies in clinical trials for HCC \[[@pone.0236622.ref008]--[@pone.0236622.ref013]\]. Multiple immunotherapeutic strategies have been tested in HCC, with some degree of success, particularly with immune checkpoint blockade (ICB).Despite the initial enthusiasm, treatment benefit is only appreciated in a modest proportion of patients. Challenges stay in identifying HCC patients who could best benefit from immunotherapy. Therefore, understanding the relationship between the immune system and prognosis is vital to effectively utilize promising immuno-oncology agents.

Tumor microenvironment (TME) cells are a vital element of tumor tissue. Recently, accumulating evidence has elucidated their clinicopathologic significance in predicting outcomes in various malignancies, including gastric cancer, ovarian cancer, neuroblastoma, and melanoma \[[@pone.0236622.ref014]--[@pone.0236622.ref017]\]. Notably, immune and stromal cells, two major components of non-tumor cell populations in the TME, have been identified as offering a prognostic assessment of the tumor \[[@pone.0236622.ref018],[@pone.0236622.ref019]\]. Yoshihara et al. designed an algorithm based on gene expression signatures to estimate immune and stromal cells, as well as tumor purity, called the Estimation of Stromal and Immune cells in Malignant Tumor Tissues using Expression Data (ESTIMATE) \[[@pone.0236622.ref020]\]. ESTIMATE scores correlate with DNA copy number-based tumor purity across samples from 11 different tumour types, profiled on Agilent, Affymetrix platforms or based on RNA sequencing and available through The Cancer Genome Atlas. The prediction accuracy is further corroborated using 3,809 transcriptional profiles available elsewhere in the public domain. The ESTIMATE method allows consideration of tumour-associated normal cells in genomic and transcriptomic studies. The ESTIMATE algorithm has since been adopted to assess many malignancies, such as lung cancer, breast cancer, prostate cancer, cholangiocarcinoma, glioblastoma, lung cancer, salivary duct carcinoma, and colon cancer \[[@pone.0236622.ref021]--[@pone.0236622.ref028]\], whereas the prognostic value of immune and/or stromal scores of liver cancer has not been sufficiently investigated.

Here, we comprehensively analyzed 346 liver cancer cases, with clinicopathologic characteristics and immune scores obtained from The Cancer Genome Atlas (TCGA), to evaluate the association of immune score with prognosis and to construct a clinical nomogram for predicting the survival of patients with liver cancer.

Material and methods {#sec006}
====================

Materials {#sec007}
---------

We used public data downloaded from the TCGA dataset for this research. TCGA ([https://portal.gdc.cancer.gov](https://portal.gdc.cancer.gov/)) is currently the largest dataset available for the genomic analysis of tumors, including at least 200 kinds of cancer and associated clinical information as well as measurements such as DNA methylation and RNA sequencing. TCGA's clinicopathological information was downloaded from an open resource, which included the unique number of patients, age, tumor node metastasis (TNM) findings, tumor grade, status, and survival time. Immune scores were downloaded from the ESTIMATE website (<https://bioinformatics.mdanderson.org/estimate>), which provides researchers with scores for tumor purity, the level of stromal cells present, and the infiltration level of immune cells in tumor tissues based on expression data. This website is designed to view and download stromal, immune, and ESTIMATE scores for each sample across all TCGA tumor types and platforms.

Data preprocessing {#sec008}
------------------

A total of 346 cases could be used for further analysis after the number of duplicates was excluded. The specific elimination analysis process is listed in ([S1 Fig](#pone.0236622.s001){ref-type="supplementary-material"}) as a flowchart. Each immune score corresponds to one patient.

Statistical analysis {#sec009}
--------------------

The cutoff point for immune score was obtained using X-tile 3.6.1 software (Yale University School of Medicine, New Haven, CT, USA), as described previously \[[@pone.0236622.ref029]\]. X-tile plots were conducted for the assessment of immune scores; this was expressed as the optimization of cutoff points based on outcome. Categorical data were analyzed using the chi-squared test or Fisher\'s exact test, and continuous variables were analyzed using the analysis of variance test or the Kruskal--Wallis H test for variables with an abnormal distribution and homogeneity of variance. Survival curves were constructed using the Kaplan--Meier method and were compared using the log-rank test. A multivariate Cox proportional-hazards regression model was used to identify the independent predictors of survival time. After the effects of age, tumor grade, TNM stage, and immune score were simultaneously considered, adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated.

A total of 346 patients were divided into high and low immune score groups according to the immune score results. The differentially expressed genes (DEGs) were identified using the package limma in R version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria), and the cutoffs were fold change \> 1 and adjust P \< 0.05. To assess the potential biologic functions of differentially expressed immune-related genes, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed by the cluster Profiler package in R. Functional categories with a adjusted P value \< 0.05 or FDR \< 0.05 were considered as significant pathways. The PPI network of DEGs was constructed according to information acquired using the STRING database (<https://string-db.org/>). To identify hub genes in the PPI network, we implemented maximal clique centrality analysis into cytoHubba (a Cytoscape plugin). Maximal clique centrality is a topological analytical method that effectively screens for hub genes. In addition, the expression of all the 10 genes was verified on the GEPIA (<http://gepia.cancer-pku.cn/>).

Nomograms were formulated based on the results of multivariate analysis using R software.These nomograms were subjected to 1000 bootstrap resamples for internal validation of the analyzed database. The performance of models for predicting prognosis was evaluated by calculating the concordance index (C-index). The value of the C-index was between 0.5 and 1.0, with 1.0 indicating the perfect ability to correctly discriminate the outcomes with the model and 0.5 indicating a random chance. Calibration of the nomogram for three and five years of survival was performed by comparing the observed survival with the predicted survival probability. All statistical tests were two-sided and p-values of less than 0.05 were considered to be statistically significant. Data compilations and descriptive statistics were performed using the IBM SPSS version 23 software program (IBM Corp., Armonk, NY, USA).

Results {#sec010}
=======

Patients' characteristics {#sec011}
-------------------------

A total of 346 patients were included in our analysis datasets after data cleaning (for specific data preparation, see [S1 Fig](#pone.0236622.s001){ref-type="supplementary-material"}). The average age of patients was 58.79 years (standard deviation: 13.46 years, range: 16--85 years). Median immune scores of patients were −108.41 (range: −1209.20 to 2934.40, interquartile range: 419.55). The cutoff points for immune score were −786.40 and 268.70; thus, patients were subsequently subdivided into high, intermediate, and low immune score subgroups (X-tile plots are shown in [S2 Fig](#pone.0236622.s002){ref-type="supplementary-material"}). In total, the scores of 35 (10.12%) patients were lower than or equal to −786.4 (low immune score subgroup), 198 (57.23%) had scores between −786.4 and 268.7 (intermediate immune score subgroup), and 113 (32.66%) patients had scores greater than 268.7 (high immune score subgroup). The median survival time was 542.50 days (range: 0--3675 days). [Table 1](#pone.0236622.t001){ref-type="table"} presents the clinicopathologic features of the different subgroups according to immune score. As compared with the low immune score subgroup, the patients with intermediate and high immune scores tended to be stages II and III.

10.1371/journal.pone.0236622.t001

###### Associations between clinicopathological features and immune scores in 346 liver cancer patients.

![](pone.0236622.t001){#pone.0236622.t001g}

  Immune scores                                 
  --------------- ----- ---- ----- ----- ------ ------
  Sample sizes    346   35   198   113          
  Age (y)                                6.16   0.63
  \< 40           32    5    17    10           
  40--49          38    2    25    11           
  50--59          93    13   47    33           
  60--69          112   8    67    37           
  ≥ 70            71    7    42    22           
  Tumor grade                            4.68   0.59
  G1              46    6    28    12           
  G2              169   12   98    59           
  G3              118   16   65    37           
  G4              13    1    7     5            
  Stage                                  8.53   0.20
  Stage I         171   12   96    63           
  Stage II        85    8    49    28           
  Stage III       84    14   49    21           
  Stage IV        6     1    4     1            

p \< 0.05; difference was statistically significant.

Multivariate analyses for survival time {#sec012}
---------------------------------------

Results of the multivariate Cox proportional-hazards regression analyses are shown in [Table 2](#pone.0236622.t002){ref-type="table"} and [S3 Fig](#pone.0236622.s003){ref-type="supplementary-material"}, [S4 Fig](#pone.0236622.s004){ref-type="supplementary-material"}. In comparison with patients with low immune scores, those with intermediate and high immune scores had significantly improved survival time \[HR and 95% CI: 0.54 (0.30--0.97) and 0.51 (0.27--0.97), respectively\]. As expected, when compared with patients with stage I disease, those with stage III or IV disease had significantly poorer survival time (HRs and 95% CIs for stages II, III, and IV were 1.37 (0.82--2.31 2.71 (1.74--4.23), and 6.26 (2.08--18.78), respectively). As for the rest of the clinical characteristics, significant associations were not recognized.

10.1371/journal.pone.0236622.t002

###### Multivariate analyses of survival time among liver cancer patients according to clinical characteristics and immune scores.

![](pone.0236622.t002){#pone.0236622.t002g}

                 survival time        
  -------------- -------------------- -----------------------------------------------
  Age                                 
  \< 40          1                    
  40--49         1.12 (0.47--2.71)    0.80
  50--59         1.12 (0.52--2.41)    0.78
  60--69         1.15 (0.54--2.44)    0.72
  ≥ 70           1.74 (0.82--3.69)    0.15
  Tumor grade                         
  G1             1                    
  G2             1.17 (0.64--2.16)    0.61
  G3             1.25 (0.66--2.34)    0.50
  G4             2.44 (0.88--6.77)    0.09
  Stage                               
  Stage I        1                    
  Stage II       1.37 (0.82--2.30)    0.23
  Stage III      2.71 (1.74--4.23)    \< 0.001[\*](#t002fn001){ref-type="table-fn"}
  Stage IV       6.26 (2.08--18.78)   0.001[\*](#t002fn001){ref-type="table-fn"}
  Immune score                        
  Low            1                    
  Medium         0.54 (0.30--0.97)    0.04[\*](#t002fn001){ref-type="table-fn"}
  High           0.51 (0.27--0.97)    0.041[\*](#t002fn001){ref-type="table-fn"}

\* p \< 0.05; difference was statistically significant.

Differentially expressed genes and functional enrichment analysis {#sec013}
-----------------------------------------------------------------

A total of 1122 genes (1041 upregulated and 81 downregulated) were identified as differentially expressed in high immune score groups compared with and low immune score groups. The 1122 differentially expressed immune-related genes were further analyzed by GO and KEGG analysis. GO analysis revealed that primary functional categories in the biological processes (BP) were T cell activation, leukocyte migration and leukocyte cell-cell adhesion. For cellular components (CC), the major enriched GO terms were external side of plasma membrane and collagen-containing extracellular matrix. The most enriched molecular function (MF) were receptor cytokine activity, chemokine activity and receptor ligand activity. ([S5A Fig](#pone.0236622.s005){ref-type="supplementary-material"}). KEGG pathway indicated that the differentially expressed immune-related genes were mainly involved in Cytokine-cytokine receptor interaction, Hematopoietic cell lineage and Chemokine signaling pathway. ([S5B Fig](#pone.0236622.s005){ref-type="supplementary-material"}). The results of Cytoscape showed that 33 genes were related to each other ([S6A Fig](#pone.0236622.s006){ref-type="supplementary-material"}). According to cytoHubba plugin's Degree ranking, the top 10 hub genes were *CXCL8*, *SYK*, *CXCL12*, *CXCL10*, *CXCL1*, *CCL5*, *CCL20*, *LCK*, *CXCL11*, *CCR5*([S6B Fig](#pone.0236622.s006){ref-type="supplementary-material"}). In addition, we found that highly expressed *CXCL8* and *CXCL1* had a poor Overall survival (OS)([S7 Fig](#pone.0236622.s007){ref-type="supplementary-material"}).

### Prognostic nomogram for survival time {#sec014}

The prognostic nomogram that integrated all considered independent factors for survival time is shown in [S8 Fig](#pone.0236622.s008){ref-type="supplementary-material"}. The C-index for survival time prediction was 0.66 (95% CI: 0.60--0.71). The calibration plot for the probability of survival at three and five years showed good agreement between prediction by the nomogram and actual observations ([S9 Fig](#pone.0236622.s009){ref-type="supplementary-material"}).

Discussion {#sec015}
==========

In the current study, we evaluated the prognostic significance of immune scores by using gene expression data from patients with liver cancer. After possible confounders were considered, we found that high and/or intermediate immune scores were significantly associated with the survival time of liver cancer patients. Importantly, we found that immune related genes *CXCL8* and *CXCL1* are related to prognosis. Meanwhile, we also constructed nomograms to easily predict the survival of patients with liver cancer.

The initiation and progression of liver cancer, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, are dependent on the tumor microenvironment. Immune cells are key players in the liver cancer microenvironment and conduct complicated crosstalk with cancer cells. The prognostic importance of immune cell infiltration has been recognized for different solid tumor types \[[@pone.0236622.ref021],[@pone.0236622.ref022],[@pone.0236622.ref030],[@pone.0236622.ref031]\]. It has been previously reported that T- and B-cells are present in immune cell infiltrates of hepatocellular carcinoma (HCC) and that the degrees of tumor-infiltrating T- and B-cells correlate with improved survival of HCC patients \[[@pone.0236622.ref032]\]. Furthermore, immune scores calculated from gene expression data were used to indicate immune signatures and even estimate the infiltration of immune cells in tumor tissue. In our study, based on TCGA data, the clinicopathological information and immune scores of liver cancer patients were used to explore the relationship between immune scores and prognosis. When adjusted for possible confounders, higher immune scores significantly conferred longer survival times among liver cancer patients. The possible reason for this is that higher immune scores indicated an enhanced immune system and function, which could be mobilized to increase the antitumor immunity of tumor microenvironments so as to control and eliminate the tumor \[[@pone.0236622.ref033]\]. This is also verified by functional analysis of differentially expressed genes with different immune scores.

Cancer immunotherapy has achieved positive clinical responses in the treatment of various cancers, including liver cancer \[[@pone.0236622.ref034],[@pone.0236622.ref035]\]. Immune checkpoint inhibitors have emerged as potentially effective treatments for patients with HCC in the advanced stage \[[@pone.0236622.ref036]\]. Clinical experience with checkpoint inhibitors in HCC includes early trials with the anti--cytotoxic T-lymphocyte-associated protein 4 agent tremelimumab and a large phase II trial with the anti--programmed cell death protein 1 agent nivolumab. The latter has shown strong activity---particularly as second-line therapy---both in terms of tumor response and patient survival \[[@pone.0236622.ref008],[@pone.0236622.ref037]\]. However, immunotherapy of patients with HCC in the advanced stage remains a great challenge, with very few drugs approved. Therefore, immune scores may not only be used as prognostic biomarkers for liver cancer patients but also have potential clinical values in the choice of immunotherapeutic strategy. At the same time, we constructed a nomogram of liver cancer survival time based on clinicopathological characteristics and immune scores.

*CXCL8* and *CXCL1* belong to the CXC chemokine family, which acts as an important multifunctional cytokine to modulate tumour proliferation, invasion and migration in an autocrine or paracrine manner \[[@pone.0236622.ref038]\]. *CXCL8* mediated tumor progression, occurring primarily through CXC receptor 1 (*CXCR1*) and CXC receptor 2 (*CXCR2*),has been identified as a function of the modulation of angiogenesis, immune cell infiltration, cell motility, cell survival, and growth in the microenvironment as well as the regulation of local antitumor immune responses \[[@pone.0236622.ref039]\]. Huang et al. reported that down regulation of *CXCR1* dramatically reduced HCC cell migration, invasion in vitro and lung metastasis in mice model, and HCC patients with positive expression of *CXCL8* or *CXCR1* had shorter overall survival time and higher recurrence rate compared with those with negative expression \[[@pone.0236622.ref040]\]. *CXCL8* also integrates with multiple intracellular signalling pathways to produce coordinated effects.*PI3K*/*Akt* pathway is a major downstream signaling pathway of IL-8 inducing cancer cell migration, invasion, and metastasis \[[@pone.0236622.ref041],[@pone.0236622.ref042]\].Numerous studies showed that activation of the *PI3K*/*Akt* signaling pathway was critical to the development and progression of HCC and could modulate the malignant behavior of HCC \[[@pone.0236622.ref043],[@pone.0236622.ref044]\]. The *Ras*/*MAPK* pathway is activated in 50--100% of human HCCs and is related to a poor prognosis \[[@pone.0236622.ref045]\]. *MAPK* signalling cascade consists of multiple serine/threonine kinases among which the best characterised is the *Raf-1*/*MAP/Erk* cascade. *CXCL8* activates this classic signalling cascade in both neutrophils and cancer cells \[[@pone.0236622.ref046]\]. *CXCL1* was regulated by multiple signal pathways and tumor microenvironment. Accumulating evidence has proved that *CXCL1* plays an important role in the development of various malignant tumors. *CXCL1* contributes to tumor-associated neutrophils infiltration in lung cancer which promotes tumor growth \[[@pone.0236622.ref047]\]. In colon cancer, increased *CXCL1* expression is associated with tumor size, stage, depth of invasion, lymph node metastasis, and patient survival \[[@pone.0236622.ref048]\]. In this study, we screened out 10 core genes through protein network analysis. By analyzing their relationship with the prognosis of liver cancer, we found the highly expressed *CXCL8* and *CXCL1* are related to the prognosis of liver cancer. Therefore, targeted-inhibition of *CXCL8* or *CXCL1* may be an attractive therapeutic strategy to increase the survival of liver patients. *CXCL8* or *CXCL1* may offer effective approaches for the development of targeted molecular therapeutics for liver cancer.

Some limitations should be noted in our study. Firstly, there was no correlation between survival time and tumor grade because of an insufficient sample size in our analysis. Second, Because of the lack of data about lymph node metastasis in TCGA data in this study, we did not build a clinical prediction model of tumor size, stage and lymph node metastasis for comparison; Third, due to the small number of liver cancer samples in TCGA database, all data samples were in the experimental group and the validation group was not split. Further efforts to collect data relating to immune gene expression and working to incorporate more clinicopathological factors are encouraged to further enhance our models. Also, limited by lack of the treatment information of liver cancer in the TCGA dataset, we were unable to adjust for the effect of treatment on prognosis. Further research is needed to collect these personal characteristics to improve and verify our models.

Finally, we hope that, with this model, patients and physicians can achieve an individualized survival prediction. Identifying individual subsets that distinguish between different survival risk levels may have an impact on treatment options. Moreover, *CXCL8* or *CXCL1* inhibition warrants further investigation as a candidate therapeutic target in liver cancer.

Supporting information {#sec016}
======================

###### The database-specific elimination analysis process.

(TIF)

###### 

Click here for additional data file.

###### The cutoff points of immune scores by X-tile plotting.

Low immune score subgroup:-1209.2 to -786.4; intermediate immune score subgroup:-786.4 to 268.7; high immune score subgroup:268.7 to 2934.4

(TIF)

###### 

Click here for additional data file.

###### Kaplan--Meier curves depicting associations of immune score subgroup survival times among patients with liver cancer.

Kaplan--Meier curves depicting that in comparison with patients with low immune scores, those with intermediate and high immune scores had significantly improved survival time. p \< 0.05; difference was statistically significant.

(TIFF)

###### 

Click here for additional data file.

###### Multivariate analyses of survival time among liver cancer patients.

Multivariate analyses of survival time among liver cancer patients, when compared with patients with stage I disease, those with stage III or IV disease had significantly poorer survival time; in comparison with patients with low immune scores, those with intermediate and high immune scores had significantly improved survival time. p \< 0.05; difference was statistically significant.

(TIF)

###### 

Click here for additional data file.

###### Functional enrichment analysis of differentially expressed immune-related genes.

A. Gene ontology analysis: From top to bottom, the figure represents biological process, cellular component and molecular function, respectively. B. The most significant Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The larger the circle, the more genes it contained; conversely, the smaller the circle, the fewer genes it contained. The color of the circle is correlated with the P-value. The smaller the P-value is, the closer it is to the red value. The larger the P-value is, the closer it is to the blue value.

(TIFF)

###### 

Click here for additional data file.

###### The PPI network and hub genes.

A. PPI network diagram of 33genes. B. The network diagram of top 10 hub genes. PPI--protein-protein interaction

(TIFF)

###### 

Click here for additional data file.

###### The Overall survival of CXCL8 and CXCL1.

A. Overall survival of CXCL8. B. Overall survival of CXCL1.

(TIFF)

###### 

Click here for additional data file.

###### Liver cancer survival nomograms.

In these nomograms, each individual patient's value is located on each variable axis and a line is drawn upward to determine the number of points received for each variable value. The sum of these numbers is placed on the total points axis and a line is drawn downward to the survival axes to determine the likelihood of three- or five-year survival.

(TIFF)

###### 

Click here for additional data file.

###### The calibration curve of survival time at three and five years for liver cancer.

Nomogram-predicted probability of survival time is plotted on the x-axis; actual survival time is plotted on the y-axis.

(TIFF)

###### 

Click here for additional data file.
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6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236622.r002

Author response to Decision Letter 0

16 May 2020

Dear Prof. Sai-Ching Jim Yeung

Thanks a lot for having reviewed our manuscript. Now we have revised the manuscript according to the academic editor and reviewers' comments. Most of the revisions are in the manuscript.

Response to the academic editor

Question1: Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Answer1: We ensure that our manuscript meets PLOS ONE\'s style requirements.

Question2: Please provide the accession number of URL link to the specific TCGA dataset used in your study.

Answer2: We provide the accession number of URL link to the specific TCGA dataset used in our study.

Question3: The nomogram should be applicable to the entire range of possible score. The maximum of total points is 215, not 200. The font size of the labeling on Figure 3 and Figure 6 should be larger

Answer3: We have made changes according to the above requirements of the editor.

Response to Reviewer \#1:

Question 1: The proportional hazard assumption for multivariate Cox regression is questionable with crossing survival curves.

Answer1: Compared with the low immune score group, the p value of survival curve of medium or high immune scores group was less than 0.05, the difference was statistically significant. The cross of survival curve is mainly between the medium and high immune scores group, but there is no statistical significance between the medium and high immune scores groups. Kaplan--Meier curves depicting that in comparison with patients with low immune scores, those with medium and high immune scores had significantly improved survival time, so we think that the proportional hazard assumption for multivariate Cox regression is reliable.

Question 2: A comparison to other clinical nomograms without using immune score for liver cancer is needed.

Answer2: In clinic, we usually use tumor size, stage, lymph node metastasis to evaluate the prognosis of patients. Because of the lack of data about lymph node metastasis in TCGA data in this study, we did not build a clinical prediction model of tumor size, stage and lymph node metastasis for comparison. Our study aims to reveal the value of immune score in clinical prediction model and improve the basis for immunotherapy of liver cancer.

Question 3: It could be risky to apply the proposed nomogram based on the limited sample size in this study without external validation.

Answer3: Due to the small number of liver cancer samples in TCGA database, all data samples were in the experimental group and the validation group was not split. This is not only the deficiency of this study, but also the direction of the later study. Later, we plan to build a liver cancer data bank for further verification.

Response to Reviewer \#2:

Question 1: Many statements throughout the manuscript lack appropriate references. In introduction section, authors should update most recent HCC clinical and basic research literatures. These should be added where appropriate. The ESTIMATE---a key method they used in this study to evaluate HCC samples but less described in details. Overall, the result section is also too simple and does not focus on what is the significance of the data on HCC study.

Answer1: In introduction section, we add some clinical immune related studies of liver cancer and elaborate the ESTIMATE. In the results section, by analyzing the expression of different genes in the groups with high and low immune scores, we can screen out the target genes that may guide the clinical prognosis of liver cancer to further enrich our results.

Question 2: TCGA also provide normal liver samples either adjacent liver tissues to liver tumor in same patient or nonmalignant liver tissues they collected. It is important to compare the immunoscore not only in HCC but also in nonmalignant liver tissues that may reflect whole liver tumor microenvironment and immunity in liver.

Answer2: As the reviewer said, if there is an immune score of adjacent liver tissues to liver tumor in same patient, it will better reflect the whole tumor microenvironment. Although TCGA database has case data of normal liver tissue, there is no case data of adjacent liver tissues to liver tumor in same patient, and TCGA only has corresponding clinical data of cancer cases; secondly, The ESTIMATE database only has corresponding immune score of cancer patients, so the current data can only reveal immune score of microenvironment of liver cancer.

Question 3: It is important to provide and describe what the novelty of the present study is, not only somewhat incremental given that this immunoscore has been shown in other many cancer types.

Answer3: We further analyzed and screened the immune genes related to the prognosis of liver cancer, and provided theoretical basis for the research of liver cancer clinical targeted drugs.

Question4: What are the specific immune or stromal makers or immune genes in this HCC data set, such as inflammation cytokines, TGF-beta genes, and exclusive/exhaustive T cell markers? They only show a general correlation between the Score and patient survival in HCC samples. It would strengthen to show some specific immune marker correlations. These data will provide important information for clinical use.

Answer4: Through the analysis of differential gene expression in the high and low immune score groups, we screened out 10 target genes, and further analyzed that a and B are related to the prognosis of liver cancer, so as to provide basis for the research and development of clinical targeted drugs for liver cancer.

Question5: Figure legend is too simple. The patients' information they analyzed and the statistics should be included in. In the Fig.3, what is the detail method they used to get this p value 0.025? is it among 3 groups? Or only low group vs. high/medium groups? It looks like no significant between high and medium?

Answer5: Figure 3 has been modified.
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Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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12 Jun 2020

PONE-D-20-05913R1

A new clinical prognostic nomogram for liver cancer based on immune score

PLOS ONE

Dear Dr. Shen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 27 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Sai-Ching Jim Yeung, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

The responses to the Reviewers\' comments were inadequate.

Response to Reviewer\#1 Question 1: Reviewer\#1 is concerned about the proportional hazard assumption for the Cox regression model. Since Reviewer\#1 raised the concern based on the appearance of the Kaplan-Meier curves, the authors should run diagnostic tests for Cox regression model: e.g.,

•Schoenfeld residuals to check the proportional hazards assumption

•Martingale residual to assess nonlinearity.

Response to Reviewer\#1 Question 2: The inability to build a clinical prediction model for comparison should be discussed as a limitation of the study in the Discussion section.

Response to Reviewer\#1 Question 3: Again, this limitation of small number liver cancer samples is another limitation of the study that should be mentioned in the Discussion section.

Response to Reviewer\#2 Question 2: Although the ESTIMATE database only has the corresponding immune scores of the cancer samples, the scores for normal tissue samples can be generated. The TCGA gene expression data for the normal liver samples can be downloaded. The ESTIMATE R packages can be downloaded at <https://bioinformatics.mdanderson.org/public-software/estimate/>. The ESTIMATE scores can be generated for the normal liver samples and compared.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: (No Response)

Reviewer \#3: I am sorry but I don\'t think the authors have addressed the methodological concerns provided by the previous reviewers.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: Yes: Jian Chen

Reviewer \#3: Yes: Cielito Reyes-Gibby

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236622.r004

Author response to Decision Letter 1

18 Jun 2020

Response to Reviewer \#1:

Answer1: Response to Reviewer\#1 Question 1: Reviewer\#1 is concerned about the proportional hazard assumption for the Cox regression model. Since Reviewer\#1 raised the concern based on the appearance of the Kaplan-Meier curves, the authors should run diagnostic tests for Cox regression model: e.g.,

•Schoenfeld residuals to check the proportional hazards assumption

•Martingale residual to assess nonlinearity.

Question 1: Thanks to the reviewer\'s reminder, the reviewer\'s intention was not fully understood at the beginning, which resulted in the failure to answer the reviewer\'s questions well. Now, according to the reviewer\'s suggestion, we use R language to test the proportional hazard assumption for the Cox regression model. The results show that for age, stage, tumor grade and immune score, P＞0.05.(Figure in Response to Reviewers.docx)

Question 2: Response to Reviewer\#1 Question 2: The inability to build a clinical prediction model for comparison should be discussed as a limitation of the study in the Discussion section.

Answer2: We put this part of the deficiency in the discussion part of the article.

Question 3: Response to Reviewer\#1 Question 3: Again, this limitation of small number liver cancer samples is another limitation of the study that should be mentioned in the Discussion section.

Answer3: In the discussion part of the article, we will add some explanation on this point.

Response to Reviewer \#2:

Question 1: Response to Reviewer\#2 Question 2: Although the ESTIMATE database only has the corresponding immune scores of the cancer samples, the scores for normal tissue samples can be generated. The TCGA gene expression data for the normal liver samples can be downloaded. The ESTIMATE R packages can be downloaded at <https://bioinformatics.mdanderson.org/public-software/estimate/>. The ESTIMATE scores can be generated for the normal liver samples and compared.

Answer1: The tumor microenvironment can be better reflected by the analysis of the immune score of the adjacent tissues of liver cancer. As the reviewer said, the immune score of the normal liver tissue sample data in TCGA can be obtained through the R package, but this part of the normal tissue sample is not the adjacent contrast tissue of the liver cancer tissue.
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Dear Dr. Shen,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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Sai-Ching Jim Yeung, MD, PhD

Academic Editor
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The reviewers\' comments have been addressed.
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Dear Dr. Shen:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Sai-Ching Jim Yeung

Academic Editor

PLOS ONE
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